Literature DB >> 23467774

Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report.

Pasquale De Nardo1, Rita Bellagamba, Angela Corpolongo, Elisa Gentilotti, Fabrizio Taglietti, Silvia Rosati, Mauro Galeazzi, Gian Domenico Sebastiani, Isabella Quinti, Emanuele Nicastri.   

Abstract

Anti-tumor necrosis factor alpha (anti-TNF-α) is used in the treatment of rheumatic diseases not responsive to first-line regimens. Data on the safety of anti-TNF-α in HIV-infected patients are scarce and conflicting. We describe a case of septic shock and multiorgan failure that occurred after etanercept initiation and influenza vaccination in an HIV-infected woman with rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23467774      PMCID： PMC3647743          DOI： 10.1128/CVI.00081-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  24 in total

1.  Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.

Authors:  M C Kapetanovic; T Saxne; J-A Nilsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2006-11-18       Impact factor: 7.580

2.  Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection.

Authors:  C Giannitti; M Benucci; R Caporali; S Manganelli; F Bellisai; G D Sebastiani; M Galeazzi
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Apr-Jun       Impact factor: 3.219

3.  Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis.

Authors:  Christian Zimmer; Martin Beiderlinden; Jürgen Peters
Journal:  Clin Rheumatol       Date:  2005-10-01       Impact factor: 2.980

4.  Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus.

Authors:  Chiara Giannitti; Gian Domenico Sebastiani; Stefania Manganelli; Mauro Galeazzi
Journal:  J Rheumatol       Date:  2011-04       Impact factor: 4.666

5.  Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis.

Authors:  D M Aboulafia; D Bundow; K Wilske; U I Ochs
Journal:  Mayo Clin Proc       Date:  2000-10       Impact factor: 7.616

Review 6.  Treatment of rheumatic diseases in patients with HCV and HIV infection.

Authors:  Mauro Galeazzi; Chiara Giannitti; Stefania Manganelli; Maurizio Benucci; Salvatore Scarpato; Chiara Bazzani; Roberto Caporali; Gian Domenico Sebastiani
Journal:  Autoimmun Rev       Date:  2008-08-09       Impact factor: 9.754

7.  The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

Authors:  E J Cepeda; F M Williams; M L Ishimori; M H Weisman; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-12-13       Impact factor: 19.103

Review 8.  Rheumatic conditions in human immunodeficiency virus infection.

Authors:  U A Walker; A Tyndall; T Daikeler
Journal:  Rheumatology (Oxford)       Date:  2008-04-15       Impact factor: 7.580

9.  Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.

Authors:  Nimrod Maimon; James Brunton; Adrienne K Chan; Theodore K Marras
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

10.  Successful etanercept use in an HIV-positive patient with rheumatoid arthritis.

Authors:  Primal P Kaur; Virginia C Chan; Steven N Berney
Journal:  J Clin Rheumatol       Date:  2007-04       Impact factor: 3.517
View more
  6 in total

Review 1.  Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review.

Authors:  Shen-Ju Liang; Quan-You Zheng; Yan-Long Yang; Yi Yang; Chong-Yang Liu
Journal:  Rheumatol Int       Date:  2017-03-02       Impact factor: 2.631

2.  Multisystem Inflammatory Syndrome in Adult Following COVID-19 Vaccination (MIS-AV).

Authors:  Ram Narayanan Ganapathiram; Sonia Hudson
Journal:  Indian J Crit Care Med       Date:  2022-05

3.  Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.

Authors:  Sintawat Wangsiricharoen; Colin Ligon; Lydia Gedmintas; Admad Dehrab; Marisa Tungsiripat; Clifton Bingham; Carlos Lozada; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

Review 4.  Rheumatoid arthritis in patients with HIV: management challenges.

Authors:  Matthew B Carroll; Joshua H Fields; Philip G Clerc
Journal:  Open Access Rheumatol       Date:  2016-04-29

Review 5.  Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.

Authors:  Tiphanie P Vogel; Karina A Top; Christos Karatzios; David C Hilmers; Lorena I Tapia; Pamela Moceri; Lisa Giovannini-Chami; Nicholas Wood; Rebecca E Chandler; Nicola P Klein; Elizabeth P Schlaudecker; M Cecilia Poli; Eyal Muscal; Flor M Munoz
Journal:  Vaccine       Date:  2021-02-25       Impact factor: 3.641

6.  Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up.

Authors:  Jing-Wen Chen; Guo-Shu Deng; Wen-Shuang Zhang; Ming-Ying Zhang; Tong Guan; Qiang Xu
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.